Kaysen G A, Webster S, Al-Bander H, Jones H, Hutchison F N
Department of Medicine, University of California Davis School of Medicine, 95616, USA.
Miner Electrolyte Metab. 1998;24(4):238-45. doi: 10.1159/000057376.
Urinary albumin excretion (U(alb)V) increases following dietary protein augmentation (DPA) in nephrotic humans and rats. Angiotensin-converting enzyme inhibitors (ACEI) blunt, but do not entirely prevent, increased U(alb)V at doses that reduce blood pressure and entirely block the pressor effect of exogenously administered angiotensin I (Ang-I), suggesting that angiotensin II (Ang-II) might not mediate the effect of DPA on U(alb)V. We determined the effect of losartan (Los), a specific Ang-II receptor antagonist, and compared its effect to that of enalapril (En), an ACEI, on DPA-induced increase in U(alb)V in rats with passive Heymann nephritis (HN). When Los was administered to HN rats for 48 h prior to DPA from 8.5 to 40% casein. U(alb)V increased in an identical fashion in treated and untreated rats, even though Los caused hypotension and prevented the pressor effect of infused Ang-II. Only on day 6 after DPA did U(alb)V decrease. We then measured the effect of duration of pretreatment with Los on Ang-II binding to isolated glomeruli. Maximal inhibition of Ang-II binding required treatment with Los for 6 days. We then pretreated HN rats with either En or Los for 6 days prior to DPA. In contrast to administration of Los for 2 days prior to DPA, pretreatment with either Los or En for 6 days entirely prevented any increase in U(alb)V. We then increased dietary NaCl from 0.2% to 2% (HS) to determine whether En or Los would modulate U(alb)V after DPA when Ang-II activity was suppressed. En reduced the DPA-mediated increase in U(alb)V regardless of dietary NaCl, while Los was effective only in when dietary NaCl was reduced (0.2%), suggesting that under these conditions ACEI reduces U(alb)V by a mechanism that is independent of inhibition of Ang-II and that high protein diets augment U(alb)V by both Ang-II-independent and Ang-II-dependent mechanisms.
肾病患者和大鼠在饮食中蛋白质增加(DPA)后,尿白蛋白排泄量(U(alb)V)会升高。血管紧张素转换酶抑制剂(ACEI)能减弱但不能完全阻止U(alb)V的升高,其剂量在降低血压的同时能完全阻断外源性给予的血管紧张素I(Ang-I)的升压作用,这表明血管紧张素II(Ang-II)可能不是DPA对U(alb)V产生作用的介导因素。我们测定了特异性Ang-II受体拮抗剂氯沙坦(Los)的作用,并将其与ACEI依那普利(En)对被动型Heymann肾炎(HN)大鼠DPA诱导的U(alb)V升高的作用进行了比较。在从8.5%酪蛋白到40%酪蛋白的DPA之前,给HN大鼠服用Los 48小时。尽管Los导致了低血压并阻止了注入的Ang-II的升压作用,但处理组和未处理组大鼠的U(alb)V以相同方式升高。仅在DPA后第6天U(alb)V才下降。然后我们测定了用Los预处理的持续时间对Ang-II与分离肾小球结合的影响。Ang-II结合的最大抑制需要用Los处理6天。然后在DPA之前,我们用En或Los对HN大鼠进行6天的预处理。与在DPA前2天给予Los不同,用Los或En进行6天的预处理完全阻止了U(alb)V的任何升高。然后我们将饮食中的NaCl从0.2%增加到2%(高盐饮食),以确定当Ang-II活性受到抑制时,En或Los是否会在DPA后调节U(alb)V。无论饮食中的NaCl如何,En都能减少DPA介导的U(alb)V升高,而Los仅在饮食中的NaCl降低(0.2%)时才有效,这表明在这些条件下,ACEI通过一种独立于抑制Ang-II的机制降低U(alb)V,并且高蛋白饮食通过Ang-II非依赖性和Ang-II依赖性机制增加U(alb)V。